Irinotecan Sun (Irinotecan Hydrochloride Trihydrate)

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Sun, is a topoisomerase I inhibitor presented as a sterile lyophilized powder for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients, acting to disrupt DNA replication in rapidly dividing tumor cells.

GNH USA supplies Irinotecan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe import and clinical use.

Irinotecan Sun belongs to the topoisomerase I inhibitor class and is used in colorectal cancer therapy.

- Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy.

Irinotecan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Anemia: decreased red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent treatment. - Severe colitis or intestinal perforation. - Hepatic toxicity: elevated liver enzymes or jaundice. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Severe abdominal pain or cramping. - Thromboembolic events: rare clot formation.

Prior to initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

- Monitor blood counts: perform regular CBC to detect neutropenia. - Assess liver function: check hepatic enzymes before and during treatment. - Evaluate bowel status: avoid use in patients with recent abdominal surgery or obstruction. - Dose adjustment: consider reduced dosing in patients with hepatic impairment. - Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with several drug classes, influencing efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): increase SN‑38 levels and risk of neutropenia. - Concurrent myelosuppressive agents: amplify bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may exacerbate diarrhea. - Warfarin: monitor INR as hepatic effects can alter coagulation. - Other hepatotoxic medications: increase risk of liver injury. - Proton pump inhibitors: potential impact on drug absorption. - Herbal supplements affecting CYP enzymes: assess for possible interaction.